Ireland - English - HPRA (Health Products Regulatory Authority)

leo laboratories limited - tinzaparin sodium - solution for injection - 18,000 iu in 0.9 ml international unit(s)/millilitre - heparin group; tinzaparin

Ireland - English - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - tiotropium bromide - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim international gmbh - tiotropium - inhalation powder, hard capsule - 18 microgram(s) - anticholinergics; tiotropium bromide

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet ireland limited - cefalexin sodium - suspension for injection - 18 percent weight/volume - cefalexin - cattle, dogs, cats - antibacterial

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet ireland limited - fenbendazole - oral paste - 18.75 percent weight/weight - fenbendazole - horses - endoparasiticide

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; titanium dioxide; glycerol; iron oxide yellow; polysorbate 80; iron oxide red - lecteva (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

United States - English - NLM (National Library of Medicine)

ventura corporation ltd - avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y) - avobenzone 0.0003 g in 1 g

United States - English - NLM (National Library of Medicine)

blue earth diagnostics - fluciclovine f-18 (unii: 38r1q0l1ze) (fluciclovine f-18 - unii:38r1q0l1ze) - fluciclovine f-18 221 mci in 1 ml - axumin is indicated for positron emission tomography (pet) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (psa) levels following prior treatment. none risk summary axumin is not indicated for use in females and there is no information on the risk of adverse development outcomes in pregnant women or animals with the use of fluciclovine f 18. risk summary axumin is not indicated for use in females and there is no information of the presence of fluciclovine f 18 in human milk. safety and effectiveness have not been established in pediatric patients. of the total number of patients in clinical studies of axumin, the average age was 66 years with a range of 21 to 90 years. no overall differences in safety or effectiveness were observed between older subjects and younger subjects.